Shintani Takashi, Matsuo Yukinori, Iizuka Yusuke, Mitsuyoshi Takamasa, Mizowaki Takashi, Hiraoka Masahiro
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Radiation Oncology and Image-applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Anticancer Res. 2017 Sep;37(9):5161-5167. doi: 10.21873/anticanres.11937.
BACKGROUND/AIM: To examine the prognostic significance of serum carcinoembryonic antigen (CEA) for stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT).
In total, 129 stage I NSCLC patients were analyzed and divided into two groups: CEA-High (CEA>5 ng/ml) and CEA-Low (CEA≤5 ng/ml).
Median follow-up time was 38 months. Overall survival was not significantly different between CEA-High (n=47) and CEA-Low (n=82) patients (57% vs. 63% at 3 years; p=0.39), although progression-free survival (PFS) was significantly worse in CEA-High patients (31% vs. 51% at 3 years; p=0.01). Larger tumor size and high CEA level were independent prognostic factors for worse PFS. Failure pattern analysis showed that regional node or distant recurrence was more common in CEA-High patients (47%) than in CEA-Low patients (29%).
Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully.
背景/目的：探讨血清癌胚抗原（CEA）对接受立体定向体部放疗（SBRT）的Ⅰ期非小细胞肺癌（NSCLC）患者的预后意义。
共分析129例Ⅰ期NSCLC患者，分为两组：CEA高组（CEA>5 ng/ml）和CEA低组（CEA≤5 ng/ml）。
中位随访时间为38个月。CEA高组（n = 47）和CEA低组（n = 82）患者的总生存期无显著差异（3年时分别为57%和63%；p = 0.39），尽管CEA高组患者的无进展生存期（PFS）显著更差（3年时分别为31%和51%；p = 0.01）。肿瘤体积较大和CEA水平较高是PFS较差的独立预后因素。失败模式分析显示，CEA高组患者（47%）区域淋巴结或远处复发比CEA低组患者（29%）更常见。
CEA高的Ⅰ期NSCLC患者区域或全身复发风险较高，应密切随访。
